|
|
|
|
|
|
|
11.11.26 - 00:00
|
Alcon Q3 Profit Rises 10%; Tightens FY26 Outlook (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Alcon Inc. (ALC), an eye care company offering surgical and vision care products, on Tuesday reported an increase in profit and revenues for the third quarter, driven largel......
|
|
|
|
|
10.11.26 - 22:39
|
Innovation and Product Launch Momentum Drive Alcon′s Third-Quarter 2026 Growth (Business Wire)
|
|
|
Third-quarter 2026 sales of $2.7 billion, +5%, +5% constant currency1 (cc), vs. third-quarter 2025
Year-to-date 2026 sales of $8.2 billion, +7%, +6% cc, vs. the same period last year
Third quarter 2026 diluted EPS of $0.54, +13%, +14% cc; core diluted EPS2 of $0.91, +15%, +15% cc, vs. third-quarter 2025
Returned $748 million to shareholders on a year-to-date basis
Recently announced the acquisition of Neurotech Pharmaceuticals, Inc. ("Neurotech"), strengthening our portfolio of products in retinal disease
Ad Hoc Announcement Pursuant to Art. 53 LRGENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2026. For the third quarter of 2026, sales were $2.7 billion, up 5% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.54 and core diluted earnings per share2 of $0.91 in the thi...
|
|
|
|
|
|
|
|
|
|
|
|
|
20.10.26 - 22:39
|
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 (Business Wire)
|
|
|
Expands Alcon's retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease
Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access
Broadens Alcon's offering in retinal disease
GENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases.
This acquisition expands Alcon's retina portfolio with ENCELTO™ (revakinagene taroretcel-lwey), the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. ENCEL...
|
|
|
|
|
|
|
|
|
15.10.26 - 17:18
|
Ryan Israel on Investing Beyond AI (Bloomberg)
|
|
|
As AI stocks retreat and rates remain a concern, Pershing Square CIO Ryan Israel joins Bloomberg Open Interest to explain why the firm is focused on durable businesses at attractive prices. He discusses the long-term cases for the eye-care company Alcon and Netflix, when a macro bet makes sense and the firm's expansion into private growth companies. (Source: Bloomberg)...
|
|
|
|
|
|
|
04.09.26 - 17:33
|
Mason Cisney Alcon Wealth Management Group Joins UBS in Pueblo, CO (Business Wire)
|
|
|
PUEBLO, Colo.--(BUSINESS WIRE)--UBS today announced that Financial Advisors Caitlin Alcon, Calvin Mason, and Craig Cisney will be joining the firm. They will be joining the UBS Mountain West Market, managed by Mitch Markley, and will report to Market Director Justin French.
“Caitlin, Calvin and Craig have earned the trust and respect of clients and community members through years of dedication, professionalism, and service,” said Mitch Markley, Mountain West Market Executive at UBS. “We are thrilled to welcome them to UBS and look forward to the impact they will have on our team. Their passion for helping others, both professionally and personally, reflects the culture we strive to foster every day.”
Calvin Mason brings nearly 35 years of experience in the brokerage and financial advisory business, offering a full spectrum of investment products and services to clients. A graduate of Colorado State University in Fort Collins, Calvin earned a Bachelor of Science degree in Business Administration wi...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
